Constipation Digestive System
Conditions
Interventions
Research Group 1: Qirong Runchang Oral Liquid, oral administration. 20 ml per dose, three times daily, for 7 days
Research Group 2: Congrong Tongbian Oral Liquid, oral administration. 20 ml once daily
Sponsors
Rongchang Pharmaceutical (Zibo) Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for constipation in Traditional Chinese Medicine 2. Aged between 18 and 75 years (inclusive), gender 3. Has had fewer than three spontaneous bowel movements in the past week prior to enrollment 4. The subject has understood the trial content and voluntarily signed the informed consent form, and the process of obtaining informed consent complies with GCP regulations
Exclusion criteria
Exclusion criteria: 1. Those with severe primary diseases of the heart, lungs, kidneys, brain, hematopoietic system, endocrine system, etc., or malignant tumors 2. Those with allergies to known drug components or allergic constitutions (e.g., allergies to two or more drugs or foods) 3. Those diagnosed by the investigator as having constipation or severe anal organic lesions caused by intestinal narrowing due to organic intestinal diseases (e.g., obstructive diseases, digestive tract tumors, inflammatory bowel disease, intestinal tuberculosis, etc), leading to defecation disorders 4. Those with drug-related constipation: those who have regularly used medications explicitly stated in the drug instructions to cause constipation (e.g., antispasmodics, antidiarrheals, nonsteroidal anti-inflammatory drugs) in the 4 weeks prior to screening, or those who cannot discontinue these medications during the study 5. Pregnant and breastfeeding women; male subjects and female subjects of childbearing potential who are unwilling or unable to use effective contraceptive measures during the trial 6. Those who have participated in other drug clinical trials within the past 3 months 7. Other situations deemed unsuitable for participation in this trial by the investigator
Countries
China
Contacts
Public ContactJinkai Xu
Outcome results
None listed